OBJECTIVES: The stationary phase of Clostridium difficile, which is associated with the symptoms of the diarrhoeal disease, is refractory to antibiotic killing. The aim of this study was to explore whether probiotic-derived reutericyclin and related synthetic analogues could kill stationary phase C. difficile at concentrations achievable in the gastrointestinal tract. METHODS: The bactericidal activities of reutericyclin and lead compound derivatives were examined against logarithmic and stationary phase cultures of different C. difficile strains. The absorption of compounds across the intestinal epithelia was tested using the Caco-2 permeability model. RESULTS: Unlike vancomycin and metronidazole, reutericyclins demonstrated concentration-dependent killing, being rapidly bactericidal against both logarithmic and stationary phase cells, at low concentrations (0.09-2 mg/L). The intestinal absorption of unmodified reutericyclin was poor and comparable to that of vancomycin. However, this property varied significantly for the synthetic reutericyclin analogues, ranging from well absorbed to non-absorbed. The non-absorbable compounds were highly effluxed, suggesting this parameter could be modulated to obtain agents with superior efficacy. CONCLUSIONS: Reutericyclins showed excellent potency against the lethal non-growing stage of C. difficile at concentrations that may be attained in the gastrointestinal tract. Since these agents represent novel potential treatments for C. difficile infection, further development of this compound class is warranted.
OBJECTIVES: The stationary phase of Clostridium difficile, which is associated with the symptoms of the diarrhoeal disease, is refractory to antibiotic killing. The aim of this study was to explore whether probiotic-derived reutericyclin and related synthetic analogues could kill stationary phase C. difficile at concentrations achievable in the gastrointestinal tract. METHODS: The bactericidal activities of reutericyclin and lead compound derivatives were examined against logarithmic and stationary phase cultures of different C. difficile strains. The absorption of compounds across the intestinal epithelia was tested using the Caco-2 permeability model. RESULTS: Unlike vancomycin and metronidazole, reutericyclins demonstrated concentration-dependent killing, being rapidly bactericidal against both logarithmic and stationary phase cells, at low concentrations (0.09-2 mg/L). The intestinal absorption of unmodified reutericyclin was poor and comparable to that of vancomycin. However, this property varied significantly for the synthetic reutericyclin analogues, ranging from well absorbed to non-absorbed. The non-absorbable compounds were highly effluxed, suggesting this parameter could be modulated to obtain agents with superior efficacy. CONCLUSIONS: Reutericyclins showed excellent potency against the lethal non-growing stage of C. difficile at concentrations that may be attained in the gastrointestinal tract. Since these agents represent novel potential treatments for C. difficileinfection, further development of this compound class is warranted.
Authors: Michel Warny; Jacques Pepin; Aiqi Fang; George Killgore; Angela Thompson; Jon Brazier; Eric Frost; L Clifford McDonald Journal: Lancet Date: 2005 Sep 24-30 Impact factor: 79.321
Authors: Raghunandan Yendapally; Julian G Hurdle; Elizabeth I Carson; Robin B Lee; Richard E Lee Journal: J Med Chem Date: 2008-02-19 Impact factor: 7.446
Authors: David Goulding; Harold Thompson; Jenny Emerson; Neil F Fairweather; Gordon Dougan; Gill R Douce Journal: Infect Immun Date: 2009-09-14 Impact factor: 3.441
Authors: Julian G Hurdle; Raghunandan Yendapally; Dianqing Sun; Richard E Lee Journal: Antimicrob Agents Chemother Date: 2009-07-06 Impact factor: 5.191
Authors: Thomas P Wyche; René F Ramos Alvarenga; Jeff S Piotrowski; Megan N Duster; Simone R Warrack; Gabriel Cornilescu; Travis J De Wolfe; Yanpeng Hou; Doug R Braun; Gregory A Ellis; Scott W Simpkins; Justin Nelson; Chad L Myers; James Steele; Hirotada Mori; Nasia Safdar; John L Markley; Scott R Rajski; Tim S Bugni Journal: ACS Chem Biol Date: 2017-07-26 Impact factor: 5.100
Authors: Xiaoxi B Lin; Christopher T Lohans; Rebbeca Duar; Jinshui Zheng; John C Vederas; Jens Walter; Michael Gänzle Journal: Appl Environ Microbiol Date: 2015-01-09 Impact factor: 4.792
Authors: Philip T Cherian; Xiaoqian Wu; Lei Yang; Jerrod S Scarborough; Aman P Singh; Zahidul A Alam; Richard E Lee; Julian G Hurdle Journal: J Antimicrob Chemother Date: 2015-08-18 Impact factor: 5.790
Authors: Chao Chen; Naveen K Doll; Gabriele Casadei; John B Bremner; Kim Lewis; Michael J Kelso Journal: Bioorg Med Chem Lett Date: 2013-12-10 Impact factor: 2.823
Authors: Philip T Cherian; Xiaoqian Wu; Marcus M Maddox; Aman P Singh; Richard E Lee; Julian G Hurdle Journal: Sci Rep Date: 2014-04-17 Impact factor: 4.379